Tyrosine kinase inhibitors (TKIs) target the constitutively activated BCR–ABL kinase, thus leading to a longer-term remission of CML in majority of patients, but they do not eliminate leukemia stem cells (LSCs). Here, BCR is linked to chronic myelogenous leukemia, BCR-ABL1 positive.